Global CDMO mAbxience operates as a contract development and manufacturing organization with GMP approvals and a multi-continent footprint, presenting a direct opportunity to engage biopharma partners seeking scalable biosimilar production and integrated manufacturing solutions.

Biosimilar Focus With ongoing biosimilar development in oncology and existing market approvals, there is potential to target oncology-focused biotechs and EDCs seeking partnered development and commercialization pathways.

Strategic Partnerships A robust network of 30+ partners and a history of collaborations (e.g., with Biosidus and Amneal licensing) indicates readiness for new alliances, co-development, and regional manufacturing agreements to expand reach.

Regulatory Readiness GMP-certified facilities approved by FDA and EMA position mAbxience as a trusted supplier for global markets, enabling faster third-party access, supply commitments, and potential for milestone-driven CDMO engagements.

Growth through Acquisition and Leadership Recent leadership changes and ownership by Fresenius Kabi and Insud Pharma signal scale-up opportunities, financing-backed expansion, and the possibility to offer bundled biosimilar portfolios or integrated supply services to large pharma buyers.